BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kamp WM, Sellers CM, Stein S, Lim JK, Kim HS. Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma. Sci Rep 2019;9:17081. [PMID: 31745132 DOI: 10.1038/s41598-019-53051-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Li C, Xu J. Identification of Potentially Therapeutic Target Genes of Hepatocellular Carcinoma. Int J Environ Res Public Health 2020;17:E1053. [PMID: 32046048 DOI: 10.3390/ijerph17031053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Curran C, Stanley AJ, Barclay ST, Priest M, Graham J. The association between deprivation and the incidence and survival of patients with hepatocellular carcinoma in the West of Scotland. Expert Rev Gastroenterol Hepatol 2021;:1-7. [PMID: 34689659 DOI: 10.1080/17474124.2021.1997586] [Reference Citation Analysis]
3 Turgeon MK, Lee RM, Gamboa AC, Yopp A, Ryon EL, Goel N, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Maithel SK, Russell MC. Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study. HPB (Oxford) 2021;23:422-33. [PMID: 32778389 DOI: 10.1016/j.hpb.2020.07.012] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chiu HC, Chiu YC, Yang EH, Chang TT, Chien SC, Wu IC, Wu CH, Cheng PN. Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan. J Formos Med Assoc 2021;120:983-90. [PMID: 32891488 DOI: 10.1016/j.jfma.2020.08.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Nevola R, Rinaldi L, Zeni L, Romano C, Marrone A, Galiero R, Pafundi PC, Acierno C, Vetrano E, Adinolfi LE. Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals. Expert Rev Gastroenterol Hepatol 2021;15:643-56. [PMID: 33445990 DOI: 10.1080/17474124.2021.1877136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Terashima T, Higashibeppu Y, Yamashita T, Sakata Y, Azuma M, Fujimoto K, Munakata H, Ishii M, Kaneko S. Treatment patterns and medical costs after hepatectomy in real-world practice for patients with hepatocellular carcinoma in Japan. Hepatol Res 2021. [PMID: 34288302 DOI: 10.1111/hepr.13701] [Reference Citation Analysis]
7 Sahakyan Y, Lee-Kim V, Bremner KE, Bielecki JM, Krahn MD. Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis. J Viral Hepat 2021;28:739-54. [PMID: 33556225 DOI: 10.1111/jvh.13482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Due OT, Thakkinstian A, Thavorncharoensap M, Sobhonslidsuk A, Wu O, Phuong NK, Chaikledkaew U. Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam. Value Health. 2020;23:1180-1190. [PMID: 32940236 DOI: 10.1016/j.jval.2020.03.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Tran L, Jung J, Carlin C, Lee S, Zhao C, Feldman R. Use of Direct-Acting Antiviral Agents and Survival Among Medicare Beneficiaries with Dementia and Chronic Hepatitis C. J Alzheimers Dis 2021;79:71-83. [PMID: 33216031 DOI: 10.3233/JAD-200949] [Reference Citation Analysis]
10 Lockart I, Hajarizadeh B, Alavi M, Davison S, Prakoso E, Levy MT, George J, Dore GJ, Danta M. Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival. J Viral Hepat 2021;28:710-8. [PMID: 33481322 DOI: 10.1111/jvh.13475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Sung PS, Shin EC. Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection. J Clin Med 2021;10:E221. [PMID: 33435135 DOI: 10.3390/jcm10020221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]